Original Katsura branch rice inner mesh
Great content
On February 10, the official website of NMPA showed that Qilu Pharmaceutical's isosorbide nitrate injection passed the consistency evaluation of generic drugs, which was the first one in China to be evaluated. According to data from the intranet, the sales of terminal isosorbide nitrate injections in China's public medical institutions exceeded 200 million yuan in 2020. Up to now, 94 varieties of Qilu Pharmaceutical have passed/treated as conformity evaluation.
Isosorbide nitrate is a nitrate vasodilator that achieves therapeutic goals by dilating venous volume vessels, peripheral resistance vessels, and reducing cardiac anterior and posterior loads, reducing myocardial oxygen consumption.
According to intranet data, in 2020, the sales of terminal isosorbide nitrate injections in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) exceeded 200 million yuan, and its sales in the first half of 2021 were close to 140 million yuan, an increase of 44.33% year-on-year.
Sales of terminal isosorbide nitrate injection in public medical institutions in China (unit: 10,000 yuan)
Source: Intranet China's public medical institution terminal competition pattern
The domestic listed isosorbide nitrate injection products include isosorbide nitrate injection, isosorbide nitrate for injection, isosorbide nitrate glucose injection, isosorbide nitrate sodium chloride injection, and only Qilu Pharmaceutical's isosorbide nitrate injection has been evaluated.